What is Wedbush’s Estimate for GLUE Q4 Earnings?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Analysts at Wedbush issued their Q4 2026 earnings per share estimates for shares of Monte Rosa Therapeutics in a research report issued on Thursday, May 8th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.57) per share for the quarter. Wedbush has a “Outperform” rating and a $17.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.81. The firm had revenue of $84.93 million for the quarter, compared to analyst estimates of $13.57 million.

Several other brokerages also recently issued reports on GLUE. Lifesci Capital began coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $19.00 price target for the company. Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, March 21st.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $4.04 on Monday. The company’s 50 day simple moving average is $4.97 and its 200 day simple moving average is $6.52. Monte Rosa Therapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $12.40. The firm has a market capitalization of $248.50 million, a price-to-earnings ratio of -2.21 and a beta of 1.52.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors have recently modified their holdings of GLUE. Price T Rowe Associates Inc. MD boosted its position in Monte Rosa Therapeutics by 7.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company’s stock valued at $49,391,000 after buying an additional 515,496 shares in the last quarter. Versant Venture Management LLC bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $39,231,000. Vanguard Group Inc. lifted its holdings in Monte Rosa Therapeutics by 24.5% during the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company’s stock worth $21,905,000 after buying an additional 622,134 shares during the period. BVF Inc. IL acquired a new position in Monte Rosa Therapeutics during the 4th quarter worth about $19,185,000. Finally, Marshall Wace LLP lifted its holdings in Monte Rosa Therapeutics by 187.3% during the 4th quarter. Marshall Wace LLP now owns 499,492 shares of the company’s stock worth $3,466,000 after buying an additional 325,643 shares during the period. Institutional investors and hedge funds own 79.96% of the company’s stock.

Insiders Place Their Bets

In related news, Director Chandra P. Leo bought 10,000 shares of the business’s stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $5.84 per share, for a total transaction of $58,400.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $58,400. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.